Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(05): 310-315
DOI: 10.1590/0004-282X20180035
Article

Circulating levels of neurotrophic factors are unchanged in patients with Parkinson's disease

Os níveis circulantes de fatores neurotróficos não estão alterados em pacientes com doença de Parkinson
Natalia Pessoa Rocha
1   The University of Texas Health Science Center at Houston, McGovern Medical School, Department of Psychiatry and Behavioral Sciences, Neuropsychiatry Program, Houston, TX, USA
2   Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica (LIIM), Belo Horizonte MG, Brasil
3   Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Laboratório de Neurofarmacologia, Belo Horizonte MG, Brasil
,
João Paulo Sampaio Ferreira
2   Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica (LIIM), Belo Horizonte MG, Brasil
,
Paula Luciana Scalzo
4   Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Laboratório de Neurobiologia, Belo Horizonte MG, Brasil
,
Izabela Guimarães Barbosa
2   Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica (LIIM), Belo Horizonte MG, Brasil
,
Mariana Soares de Souza
5   Santa Casa de Belo Horizonte Hospital, Departamento de Neurologia e Neurocirurgia, Belo Horizonte MG, Brasil
,
Paulo Pereira Christo
5   Santa Casa de Belo Horizonte Hospital, Departamento de Neurologia e Neurocirurgia, Belo Horizonte MG, Brasil
,
Helton José Reis
3   Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Laboratório de Neurofarmacologia, Belo Horizonte MG, Brasil
,
Antonio Lucio Teixeira
1   The University of Texas Health Science Center at Houston, McGovern Medical School, Department of Psychiatry and Behavioral Sciences, Neuropsychiatry Program, Houston, TX, USA
2   Universidade Federal de Minas Gerais, Faculdade de Medicina, Laboratório Interdisciplinar de Investigação Médica (LIIM), Belo Horizonte MG, Brasil
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

There is great evidence linking neurotrophic factor (NF) dysfunction with Parkinson's disease (PD) pathophysiology. This study was conducted to evaluate plasma levels of NFs and their possible associations with clinical symptoms in PD. For this purpose, 40 PD patients and 25 controls were subjected to a clinical evaluation and peripheral blood draw. Plasma levels of brain-derived neurotrophic factor (BDNF), pro-BDNF, neurotrophin 3, neurotrophin 4, nerve growth, glial cell line-derived neurotrophic factor and ciliary neurotrophic factor were measured by enzyme-linked immunosorbent assay. There was no significant difference between PD patients and controls regarding the plasma levels of the evaluated NFs. In addition, NF levels were not associated with disease duration, degree of motor or functional impairment, cognitive performance or severity of depressive symptoms. In conclusion, although NFs may play relevant roles in the pathophysiology of PD, the circulating levels of these molecules are not necessarily changed in patients with PD.

RESUMO

Há evidências de que alteracões nas ações exercidas por fatores neurotróficos (FNs) estejam associadas à fisiopatologia da doença de Parkinson (DP). O presente estudo foi conduzido para avaliar os níveis plasmáticos de FNs e suas possíveis associações com sintomas clínicos na DP. Para este fim, 40 pacientes com DP e 25 controles foram submetidos à avaliação clínica e coleta de sangue periférico. Os níveis plasmáticos do fator neurotrófico derivado do cérebro (BDNF), pro-BDNF, neurotrofina 3, neurotrofina 4, fator de crescimento do nervo, fator neurotrófico derivado da glia e fator neurotrófico ciliar foram avaliados por ensaio de imunoadsorção enzimática. Não houve diferença significativa entre pacientes com DP e controles quanto aos níveis plasmáticos dos FNs avaliados. Além disso, não encontramos associação entre os níveis dos FNs e duração da doença, grau de comprometimento motor ou funcional, desempenho cognitivo e gravidade dos sintomas depressivos. Em conclusão, embora os FNs possam desempenhar papéis relevantes na fisiopatologia da DP, os níveis circulantes dessas moléculas não estão necessariamente alterados em pacientes com DP.

Keywords:

Parkinson's disease - nerve growth factors - depression - biomarkers - cognition

Palavras-chave:

doença de Parkinson - fatores de crescimento neural - depressão - biomarcadores - cognição

Support

This study was funded by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).




Publication History

Received: 22 November 2017

Accepted: 22 January 2018

Article published online:
25 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4. https://doi.org/10.1136/jnnp.55.3.181
  • 2 Martí MJ, Tolosa E. Parkinson disease: new guidelines for diagnosis of Parkinson disease. Nat Rev Neurol. 2013 Apr;9(4):190-1. https://doi.org/10.1038/nrneurol.2013.47
  • 3 Lanni C, Stanga S, Racchi M, Govoni S. The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. Curr Pharm Des. 2010;16(6):698-717. https://doi.org/10.2174/138161210790883741
  • 4 Razavi S, Nazem G, Mardani M, Esfandiari E, Salehi H, Esfahani SH. Neurotrophic factors and their effects in the treatment of multiple sclerosis. Adv Biomed Res. 2015 Feb;4(1):53. https://doi.org/10.4103/2277-9175.151570
  • 5 Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 Jun;5(6):525-35. https://doi.org/10.1016/S1474-4422(06)70471-9
  • 6 Tome D, Fonseca CP, Campos FL, Baltazar G. Role of Neurotrophic Factors in Parkinson's Disease. Curr Pharm Des. 2017;23(5):809-38. https://doi.org/10.2174/1381612822666161208120422
  • 7 Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett. 1999 Jul;270(1):45-8. https://doi.org/10.1016/S0304-3940(99)00463-2
  • 8 Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat. 2001 Jun;21(4):277-88. https://doi.org/10.1016/S0891-0618(01)00115-6
  • 9 Lorigados Pedre L, Pavón Fuentes N, Alvarez González L, McRae A, Serrano Sánchez T, Blanco Lescano L et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002 Oct;952(1):122-7. https://doi.org/10.1016/S0006-8993(02)03222-5
  • 10 Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol. 2010 Apr;257(4):540-5. https://doi.org/10.1007/s00415-009-5357-2
  • 11 Ricci V, Pomponi M, Martinotti G, Bentivoglio A, Loria G, Bernardini S et al. Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients. J Clin Psychopharmacol. 2010 Dec;30(6):751-3. https://doi.org/10.1097/JCP.0b013e3181fc2ec7
  • 12 Ziebell M, Khalid U, Klein AB, et al. Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol Aging. 2012;33(2):428 e421-425. https://doi.org/10.1016/j.neurobiolaging.2010.11.010
  • 13 Wang Y, Liu H, Du XD, Zhang Y, Yin G, Zhang BS et al. Association of low serum BDNF with depression in patients with Parkinson's disease. Parkinsonism Relat Disord. 2017 Aug;41:73-8. https://doi.org/10.1016/j.parkreldis.2017.05.012
  • 14 Wang Y, Liu H, Zhang BS, Soares JC, Zhang XY. Low BDNF is associated with cognitive impairments in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Aug;29:66-71. https://doi.org/10.1016/j.parkreldis.2016.05.023
  • 15 Rocha NP, Assis F, Scalzo PL, Vieira ÉL, Barbosa IG, de Souza MS et al. Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease. Mol Neurobiol. 2017 Feb. https://doi.org/10.1007/s12035-017-0404-y
  • 16 Fahn S, Elton R. Unified parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne. DB, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park: Macmillan Health Care Information; 1987. Volume 2, p. 153-163.
  • 17 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42. https://doi.org/10.1212/WNL.17.5.427
  • 18 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. https://doi.org/10.1016/0022-3956(75)90026-6
  • 19 Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH. [Suggestions for utilization of the mini-mental state examination in Brazil]. Arq Neuropsiquiatr. 2003 Sep;61 3B:777-81. https://doi.org/10.1590/S0004-282X2003000500014
  • 20 Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec;55(11):1621-6. https://doi.org/10.1212/WNL.55.11.1621
  • 21 Beato RG NR, Formigoni AP, Caramelli P. Brazilian version of the Frontal Assessment Battery (FAB): preliminary data of administration to healthy elderly. Dement Neuropsychol. 2007;1:59-65. https://doi:10.1590/S1980-57642008DN10100010.
  • 22 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4(6):561-71. https://doi.org/10.1001/archpsyc.1961.01710120031004
  • 23 Silberman CD, Laks J, Capitão CF, Rodrigues CS, Moreira I, Engelhardt E. Recognizing depression in patients with Parkinson's disease: accuracy and specificity of two depression rating scale. Arq Neuropsiquiatr. 2006 Jun;64(2b 2B):407-11. https://doi.org/10.1590/S0004-282X2006000300011
  • 24 Tumas V, Rodrigues GG, Farias TL, Crippa JA. The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. Arq Neuropsiquiatr. 2008 Jun;66(2a 2A):152-6. https://doi.org/10.1590/S0004-282X2008000200002
  • 25 Ventriglia M, Zanardini R, Bonomini C, Zanetti O, Volpe D, Pasqualetti P et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. BioMed Res Int. 2013;2013:901082. https://doi.org/10.1155/2013/901082
  • 26 Salehi Z, Mashayekhi F. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci. 2009 Jan;16(1):90-3. https://doi.org/10.1016/j.jocn.2008.03.010
  • 27 Zoladz JA, Majerczak J, Zeligowska E, Mencel J, Jaskolski A, Jaskolska A et al. Moderate-intensity interval training increases serum brain-derived neurotrophic factor level and decreases inflammation in Parkinson's disease patients. J Physiol Pharmacol. 2014 Jun;65(3):441-8.
  • 28 Frazzitta G, Maestri R, Ghilardi MF, Riboldazzi G, Perini M, Bertotti G et al. Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study. Neurorehabil Neural Repair. 2014 Feb;28(2):163-8. https://doi.org/10.1177/1545968313508474
  • 29 Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol. 2010 Apr;257(4):524-32. https://doi.org/10.1007/s00415-009-5353-6
  • 30 Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(1):61-64. https://doi:10.1016/j.parkreldis.2010.10.003.